Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ruxo-Sim-20 trial of ruxolitinib plus simvastatin for COVID-19 respiratory failure prevention and treatment
2020-001405-23Phase 2Active
- Sponsor
- Fundación de Investigación HM Hospitales
- Start
- Apr 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of ruxolitinib and simvastatin in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Fundación de Investigación HM Hospitales. Primary endpoint: Patients achieving WHO severity grade 5 or higher. Started Apr 2020; status: active.
02
Drugs
ruxolitinibsimvastatin
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2020-001405-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001405-23.